Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study of RSLV-132 in Females With Sjögren's Disease

ClinicalTrials.gov ID: NCT06440525

Public ClinicalTrials.gov record NCT06440525. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants With Sjögren's Disease With Moderate to Severe Symptom Burden

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: * Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? * Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? * What are the blood levels of RSLV-132 over time? * What is the immune (antibody) response in the body to RSLV-132? * What is the safety profile of RSLV-132? Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS. Participants will: Take RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device

Study identification

NCT ID
NCT06440525
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Resolve Therapeutics
Industry
Enrollment
106 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2024
Primary completion
Nov 30, 2026
Completion
Feb 28, 2027
Last update posted
Jul 17, 2025

2024 – 2027

United States locations

U.S. sites
24
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
Resolve Clinical Site Chula Vista California 91910 Recruiting
Resolve Clinical Site Tustin California 92780 Recruiting
Resolve Clinical Site Boca Raton Florida 34994 Recruiting
Resolve Clinical Site Boynton Beach Florida 33467 Recruiting
Evolution Research Center Hialeah Florida 33024 Recruiting
GNP Research Hollywood Florida 33024 Recruiting
Resolve Clinical Site Miami Florida 33140 Recruiting
Life Medical Research Miami Gardens Florida 33014 Recruiting
Resolve Clinical Site Chicago Illinois 60607 Recruiting
University of Iowa Iowa City Iowa 52242 Recruiting
Tufts College Boston Massachusetts 02111-1817 Recruiting
Resolve Clinical Site Albuquerque New Mexico 87106 Recruiting
Joint and Muscle Research Institute Charlotte North Carolina 28204 Recruiting
Arthritis and Osteoporosis Consultants of the Carolinas Charlotte North Carolina 28208 Recruiting
Onsite Clinical Solutions Salisbury North Carolina 28277 Recruiting
Altoona Center for Clinical Research Duncansville Pennsylvania 16635 Recruiting
Resolve Clinical Site Nashville Tennessee 37203 Recruiting
Resolve Clinical Site Austin Texas 78757 Recruiting
Resolve Clinical Site Katy Texas 77449 Recruiting
Resolve Clinical Site McKinney Texas 75069 Recruiting
Accurate Clinical Research Richmond Texas 77089 Recruiting
Resolve Clinical Site San Antonio Texas 78215 Recruiting
Metrodora Institute Salt Lake City Utah 84119 Recruiting
Arthritis Northwest Spokane Washington 99204 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06440525, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 17, 2025 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06440525 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →